Eurestobart Biosimilar - Research Grade

Human

ENTPD1ï؟½

5mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P49961

Blue ice

CD39 (ENTPD1) is an ectonucleotidase that hydrolyzes extracellular ATP, driving adenosine-mediated immunosuppression within the tumor microenvironment. This research-grade anti-human ENTPD1 recombinant monoclonal antibody is an unconjugated, non-therapeutic analog of eurestobart, intended exclusively for research use only (RUO). It is manufactured to stringent in vivo standards as an ultra-pure, low-endotoxin formulation and available in scalable milligram (mg) to gram (g) quantities to support heavy-usage and high-throughput laboratories. The antibody suits enzyme-blocking and neutralization assays, in vitro purinergic-signaling screening, in vivo tumor immunology models, and biologics characterization, functioning as a consistent CD39-directed reference control reagent.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks